We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
WINGLORE (Bristol-Myers Squibb Australia Pty Ltd)
Product name
WINGLORE
Date registered
Evaluation commenced
Decision date
Approval time
216 (255 working days)
Active ingredients
Ipilimumab
Registration type
EOI
Indication
[TRADE NAME] in combination with ipilimumab is indicated for the treatment of adult patients with unresectable or metastatic colorectal cancer (CRC) that is MSI-H or dMMR as determined by a validated test.